The MP1- specific CTLs are amenable to subsequent genetic modification to express a CD19- specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19+ lymphoma tumor targets while maintaining HLA-restricted MP1 specificity. Here, CD19 is linked to neoplasm.